Bullous pemphigoid (BP) is an autoimmune blistering disease mainly affecting elderly individuals. Comorbidities are common in patients with BP and have been found to complicate the management and prognosis. We describe a patient with multiple comorbidities who was successfully treated with omalizumab and suggest omalizumab as a good alternative therapy for BP to prevent treatment-related complications in elderly patients with a poor general condition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314756 | PMC |
| http://dx.doi.org/10.2147/CCID.S373682 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Double Dose of Dupilumab Shows Efficacy in Treatment-Resistant Bullous Pemphigoid.
Clin Exp Dermatol
January 2025
US Dermatology Partners, Southwest Skin Specialists, Phoenix, AZ, USA.
Relationship between bullous pemphigoid and metabolic syndrome and its relevant traits: a bidirectional two-sample Mendelian randomization study.
Arch Dermatol Res
January 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, No.1 Shuai Fu Yuan Street, Dong Cheng District, Beijing, 100730, China.
Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease, affecting mostly the elderly. Metabolic syndrome (MetS) is a set of metabolic disorders including obesity, hypertension, glucose intolerance, and dyslipidemia. Observational studies have revealed a correlation between BP and MetS with controversial results and the causal relationship needs to be clarified.
View Article and Find Full Text PDFEducational Case: Bullous pemphigoid.
Acad Pathol
December 2024
Department of Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA, USA.
A case of chronic ulcerative herpes simplex virus infection in a patient with bullous pemphigoid.
J Dermatol
January 2025
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Probing into functional decline among bullous pemphigoid patients: Letter in reply.
J Eur Acad Dermatol Venereol
January 2025
Département de Dermatologie, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!